 Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 3 | 1 | 4 | | 1982 | 4 | 1 | 5 | | 1983 | 0 | 1 | 1 | | 1984 | 1 | 2 | 3 | | 1985 | 1 | 1 | 2 | | 1986 | 1 | 1 | 2 | | 1987 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1994 | 3 | 2 | 5 | | 1995 | 6 | 1 | 7 | | 1996 | 4 | 2 | 6 | | 1997 | 1 | 0 | 1 | | 1998 | 3 | 0 | 3 | | 1999 | 9 | 1 | 10 | | 2000 | 5 | 0 | 5 | | 2001 | 5 | 1 | 6 | | 2002 | 5 | 2 | 7 | | 2003 | 4 | 0 | 4 | | 2004 | 9 | 1 | 10 | | 2005 | 7 | 4 | 11 | | 2006 | 11 | 0 | 11 | | 2007 | 6 | 2 | 8 | | 2008 | 10 | 2 | 12 | | 2009 | 12 | 1 | 13 | | 2010 | 13 | 3 | 16 | | 2011 | 12 | 2 | 14 | | 2012 | 20 | 2 | 22 | | 2013 | 24 | 3 | 27 | | 2014 | 17 | 3 | 20 | | 2015 | 20 | 2 | 22 | | 2016 | 19 | 1 | 20 | | 2017 | 23 | 1 | 24 | | 2018 | 15 | 0 | 15 | | 2019 | 25 | 1 | 26 | | 2020 | 15 | 4 | 19 | | 2021 | 17 | 2 | 19 | | 2022 | 6 | 1 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Higgs EF, Bao R, Hatogai K, Gajewski TF. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer. 2022 Jun; 10(6).
-
Olson D, Luke J. A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma. Future Oncol. 2022 Jun; 18(20):2483-2487.
-
Ascierto PA, Warner AB, Blank C, Caracò C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med. 2022 05 10; 20(1):200.
-
Wach MM, Subjeck JR, Wang XY, Repasky E, Matsuzaki J, Yu H, Wang C, Fisher D, Skitzki JJ, Kane JM. Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients. Melanoma Res. 2022 04 01; 32(2):88-97.
-
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 04 30; 399(10336):1718-1729.
-
Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, McAlpine C, Holland C, Abdullah SE, Sato T. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022 Jun 10; 40(17):1939-1948.
-
Minor DR, Kim KB, Tong RT, Wu MC, Kashani-Sabet M, Orloff M, Eschelman DJ, Gonsalves CF, Adamo RD, Anne PR, Luke JJ, Char D, Sato T. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Cancer Biother Radiopharm. 2022 Feb; 37(1):11-16.
-
Ross JA, Komoda K, Pal S, Dickter J, Salgia R, Dadwal S. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27.
-
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
-
Tsujimura M, Kaku Y, Takeuchi Y, Ishida Y, Fujimoto M, Usui S, Yamada Y, Ogawa S, Shea CR, Haga H. Maturing papillomatous nevoid melanoma in the scalp mimicking recurrent melanocytic nevus: A case report of previously undescribed subtype of nevoid melanoma. Pathol Int. 2022 Jan; 72(1):59-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|